Cargando…

Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2

Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4(+) and CD8(+) T-...

Descripción completa

Detalles Bibliográficos
Autores principales: Casado, José L., Vizcarra, Pilar, Haemmerle, Johannes, Velasco, Héctor, Martín-Hondarza, Adrián, Rodríguez-Domínguez, Mario J., Velasco, Tamara, Martín, Sara, Romero-Hernández, Beatriz, Fernández-Escribano, Marina, Vallejo, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057925/
https://www.ncbi.nlm.nih.gov/pubmed/35529539
http://dx.doi.org/10.1016/j.jvacx.2022.100165
_version_ 1784698008853544960
author Casado, José L.
Vizcarra, Pilar
Haemmerle, Johannes
Velasco, Héctor
Martín-Hondarza, Adrián
Rodríguez-Domínguez, Mario J.
Velasco, Tamara
Martín, Sara
Romero-Hernández, Beatriz
Fernández-Escribano, Marina
Vallejo, Alejandro
author_facet Casado, José L.
Vizcarra, Pilar
Haemmerle, Johannes
Velasco, Héctor
Martín-Hondarza, Adrián
Rodríguez-Domínguez, Mario J.
Velasco, Tamara
Martín, Sara
Romero-Hernández, Beatriz
Fernández-Escribano, Marina
Vallejo, Alejandro
author_sort Casado, José L.
collection PubMed
description Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4(+) and CD8(+) T-cell response, respectively. Pre-existing T-cell immunity, due to past infection (46%) or cross-reactive cellular response (26%), was significantly associated with T-cell response in frequency (CD4+ T-cell, 100% vs 82% after two doses; p = 0.049) and in the magnitude of T-cell response during follow up. Furthermore, baseline CD4(+) T-cell correlated positively with the titer of specific IgG-antibodies after first and second vaccine dose. Our data demonstrate that cross-reactive T-cells correlate with a better cellular response as well as an enhanced humoral response, and we confirm the close correlation of humoral and cellular response after mRNA vaccination.
format Online
Article
Text
id pubmed-9057925
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90579252022-05-02 Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2 Casado, José L. Vizcarra, Pilar Haemmerle, Johannes Velasco, Héctor Martín-Hondarza, Adrián Rodríguez-Domínguez, Mario J. Velasco, Tamara Martín, Sara Romero-Hernández, Beatriz Fernández-Escribano, Marina Vallejo, Alejandro Vaccine X Short communication Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4(+) and CD8(+) T-cell response, respectively. Pre-existing T-cell immunity, due to past infection (46%) or cross-reactive cellular response (26%), was significantly associated with T-cell response in frequency (CD4+ T-cell, 100% vs 82% after two doses; p = 0.049) and in the magnitude of T-cell response during follow up. Furthermore, baseline CD4(+) T-cell correlated positively with the titer of specific IgG-antibodies after first and second vaccine dose. Our data demonstrate that cross-reactive T-cells correlate with a better cellular response as well as an enhanced humoral response, and we confirm the close correlation of humoral and cellular response after mRNA vaccination. Elsevier 2022-05-02 /pmc/articles/PMC9057925/ /pubmed/35529539 http://dx.doi.org/10.1016/j.jvacx.2022.100165 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Short communication
Casado, José L.
Vizcarra, Pilar
Haemmerle, Johannes
Velasco, Héctor
Martín-Hondarza, Adrián
Rodríguez-Domínguez, Mario J.
Velasco, Tamara
Martín, Sara
Romero-Hernández, Beatriz
Fernández-Escribano, Marina
Vallejo, Alejandro
Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
title Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
title_full Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
title_fullStr Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
title_full_unstemmed Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
title_short Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
title_sort pre-existing t cell immunity determines the frequency and magnitude of cellular immune response to two doses of mrna vaccine against sars-cov-2
topic Short communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057925/
https://www.ncbi.nlm.nih.gov/pubmed/35529539
http://dx.doi.org/10.1016/j.jvacx.2022.100165
work_keys_str_mv AT casadojosel preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2
AT vizcarrapilar preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2
AT haemmerlejohannes preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2
AT velascohector preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2
AT martinhondarzaadrian preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2
AT rodriguezdominguezmarioj preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2
AT velascotamara preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2
AT martinsara preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2
AT romerohernandezbeatriz preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2
AT fernandezescribanomarina preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2
AT vallejoalejandro preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2